The Trump administration is preparing to announce a deal this week with Eli Lilly and Novo Nordisk to lower the price of their weight loss drugs, a person familiar with the plan said.

Eli Lilly and Company announced promising results for its next-generation weight-loss drug Thursday, with patients losing up to 20.1 percent of their body weight on eloralintide.

President Trump's plan drops the price of Ozempic and Wegovy for Americans, with plans for Medicare to cover the popular GLP-1 weight loss drugs.

Middle-class Indians trying to lose weight are embracing drugs such as Mounjaro, which is also used to treat diabetes in a country that has been called the world’s diabetes capital.

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels.

This article was reviewed by Darragh O’Carroll, MD. Long-Term Side Effects of Wegovy® Key takeaways: The long-term side effects of Wegovy® may include problems with your

The Trump administration announced deals with Novo Nordisk and Eli Lilly to slash weight-loss drug costs. President Trump called the deals "a triumph for American patients."

The real snag will come in the next decade: The U.S. represents 50% of group sales for Novo, and while there is a “good runway” until the early 2030s, that’s when patents in America run out and the true battle begins.